Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 7 min ago
Peer-reviewedCC BY-NC-ND 4.0Annals of Clinical and Translational Neurology

Efficacy of Fampridine on Refractory Optic Neuritis in Neuromyelitis Optica Spectrum Disorders

  • Hongxuan Wang1
  • Wanru Chen1
  • Xiangpen Li2
  • Hengjian Lu1
  • Chenguang Li1
  • Xiaoni Zhang1
  • Lulu Bu1
  • Xiaoyu Xu3
  • Qingyu Shen1
  • Ying Peng1
  1. 1Department of Neurology Sun Yat‐sen Memorial Hospital, Sun Yat‐sen University Guangzhou China
  2. 2Department of Neurology Shenshan Medical Center of Sun Yat‐sen Memorial Hospital Shanwei China
  3. 3State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center Sun Yat‐sen University Guangzhou China
Read full textPDFDOICite

Abstract

Background: Neuromyelitis optica spectrum disorders (NMOSD) usually occur with acute refractory optic neuritis (ON). However, there is a lack of efficacious treatments to improve recovery. Since fampridine has been found to improve the prognosis of multiple sclerosis (MS) and MS‐related ON, it is necessary to explore the efficacy of fampridine on visual functions in NMOSD‐ON.

Methods: Patients aged 14–80 who suffered from acute refractory AQP4‐IgG positive ON within 2 weeks onset and with high‐dose corticosteroid treatment were included. Patients treated with sustained‐release fampridine (4‐aminopyridine, 4‐AP) as add‐on treatment for 3 months were compared with patients without 4‐AP (non‐4‐AP). Visual functional scores (VFS), Opticospinal Impairment Scale (OSIS), the logarithm of the minimum angle of resolution (LogMAR) of visual acuity (VA), the mean deviation (MD) value of the static visual field, and retina nerve fiber layer (RNFL) thickness were measured and followed up from baseline to 6 months.

Results: Patients with 4‐AP add‐on treatment improved VFS or OSIS greater than that with control (non‐4‐AP) at 3 and 6 months compared with baseline (all p < 0.05). 4‐AP add‐on treatment also increased the proportion of better improvement of ON (VFS ≤ 2) at 3 months (36.4% vs. 7.1% in control, p < 0.05 adjusted for plasma exchange), and 4‐AP improved visual field at 6 months (p < 0.05 adjusted for plasma exchange).

Conclusion: Fampridine as an add‐on treatment has potential functional benefit on refractory NMOSD‐ON and improves visual functions after the attack of ON.

Related

  1. Efficacy and safety of ultrasound-guided microwave “Near-Total Ablation” for refractory hyperthyroidism: a retrospective study
    Fenglin Wu, Shicong Song, Junyu Xue +4
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC
  2. Efficacy and safety of P2X3 receptor antagonists in refractory or unexplained chronic cough: an updated systematic review and meta-analysis
    Yu-Tong An, Shu-Ze Tang, Yi Luo +2
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  3. Striking leflunomide efficacy against refractory cutaneous sarcoidosis
    Gérôme Bohelay, Jean-David Bouaziz, Hilario Nunes +4
    Journal of The American Academy of DermatologyPeer-reviewedCC BY-NC-NDFull text12 citedPhysiologyHAL
  4. 1187 Safety and efficacy of cesalatamig, a novel PD-1/VEGF bispecific antibody, as monotherapy in PD-(L)1–resistant/refractory NSCLC: Results from global, multicenter, open-label phase 1/2 studies
    Yang Liu, Yu Liu, Fawzi Abu Rous +31
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  5. Efficacy analysis and adverse event management of selinexor in the treatment of relapsed/refractory multiple myeloma.
    Zengli Kuang, Yu Chen, Cuiai Ren
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{wang2026efficacy,
  title = {{Efficacy of Fampridine on Refractory Optic Neuritis in Neuromyelitis Optica Spectrum Disorders}},
  author = {Hongxuan Wang and Wanru Chen and Xiangpen Li and Hengjian Lu and Chenguang Li and Xiaoni Zhang and Lulu Bu and Xiaoyu Xu and Qingyu Shen and Ying Peng},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  month = oct,
  doi = {10.1002/acn3.70557},
  url = {https://doi.org/10.1002/acn3.70557},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Efficacy of Fampridine on Refractory Optic Neuritis in Neuromyelitis Optica Spectrum Disorders
AU  - Hongxuan Wang
AU  - Wanru Chen
AU  - Xiangpen Li
AU  - Hengjian Lu
AU  - Chenguang Li
AU  - Xiaoni Zhang
AU  - Lulu Bu
AU  - Xiaoyu Xu
AU  - Qingyu Shen
AU  - Ying Peng
PY  - 2026
DA  - 2026/10/27
JO  - Annals of Clinical and Translational Neurology
DO  - 10.1002/acn3.70557
UR  - https://doi.org/10.1002/acn3.70557
AB  - Background: Neuromyelitis optica spectrum disorders (NMOSD) usually occur with acute refractory optic neuritis (ON). However, there is a lack of efficacious treatments to improve recovery. Since fampridine has been found to improve the prognosis of multiple sclerosis (MS) and MS‐related ON, it is necessary to explore the efficacy of fampridine on visual functions in NMOSD‐ON.  Methods: Patients aged 14–80 who suffered from acute refractory AQP4‐IgG positive ON within 2 weeks onset and with high‐dose corticosteroid treatment were included. Patients treated with sustained‐release fampridine (4‐aminopyridine, 4‐AP) as add‐on treatment for 3 months were compared with patients without 4‐AP (non‐4‐AP). Visual functional scores (VFS), Opticospinal Impairment Scale (OSIS), the logarithm of the minimum angle of resolution (LogMAR) of visual acuity (VA), the mean deviation (MD) value of the static visual field, and retina nerve fiber layer (RNFL) thickness were measured and followed up from baseline to 6 months.  Results: Patients with 4‐AP add‐on treatment improved VFS or OSIS greater than that with control (non‐4‐AP) at 3 and 6 months compared with baseline (all p < 0.05). 4‐AP add‐on treatment also increased the proportion of better improvement of ON (VFS ≤ 2) at 3 months (36.4% vs. 7.1% in control, p < 0.05 adjusted for plasma exchange), and 4‐AP improved visual field at 6 months (p < 0.05 adjusted for plasma exchange).  Conclusion: Fampridine as an add‐on treatment has potential functional benefit on refractory NMOSD‐ON and improves visual functions after the attack of ON.
SN  - 2328-9503
ER  -